Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future
M Pan, H Zhao, R Jin, PSC Leung, Z Shuai - Frontiers in Immunology, 2023 - frontiersin.org
Anti-neutrophil cytoplasmic autoantibodies (ANCA) associated vasculitis (AAV) is a
necrotizing vasculitis mainly involving small blood vessels. It is demonstrated that T cells are …
necrotizing vasculitis mainly involving small blood vessels. It is demonstrated that T cells are …
Immune checkpoint molecules in prevention and development of asthma
Z Kanannejad, S Soleimanian, Z Ghahramani… - Frontiers in …, 2023 - frontiersin.org
Allergic asthma is a respiratory disease initiated by type-2 immune responses characterized
by secretion of alarmins, interleukin-4 (IL-4), IL-5, and IL-13, eosinophilic inflammation, and …
by secretion of alarmins, interleukin-4 (IL-4), IL-5, and IL-13, eosinophilic inflammation, and …
[HTML][HTML] Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
F Fa'ak, M Buni, A Falohun, H Lu, J Song… - … for immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Management of immune-related adverse events (irAEs) is important as they
cause treatment interruption or discontinuation, more often seen with combination immune …
cause treatment interruption or discontinuation, more often seen with combination immune …
Airway disorders associated with immune checkpoint inhibitor therapy: two case reports and a systematic review
N Kawakami, H Saito, S Takahashi, S Kajie, R Kato… - Seminars in …, 2022 - Elsevier
Immune checkpoint inhibitors (ICI) are widely used for the treatment of various malignant
neoplasms. Interstitial lung disease is a well-known immune-related adverse event …
neoplasms. Interstitial lung disease is a well-known immune-related adverse event …
Successful management of severe bronchial asthma exacerbated by Anti‐PD‐L1 treatment: A report of two cases
T Sumi, Y Nagahisa, K Matsuura… - Respirology Case …, 2021 - Wiley Online Library
Immune checkpoint inhibitors (ICIs) have been used for various carcinomas. However,
immune‐related adverse events have been observed. There have been few reports of …
immune‐related adverse events have been observed. There have been few reports of …
[HTML][HTML] A Scoping Review of Vasculitis as an Immune-Related Adverse Event from Checkpoint Inhibitor Therapy of Cancer: Unraveling the Complexities at the …
CM Lee, M Wang, A Rajkumar, C Calabrese… - Seminars in Arthritis and …, 2024 - Elsevier
ABSTRACT Background/Purpose Vasculitis as an immune-related adverse event (irAE) from
checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known …
checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known …
Mucocutaneous adverse events to immune checkpoint inhibitors
F Muhaj, PV Karri, W Moody, A Brown, AB Patel - Frontiers in Allergy, 2023 - frontiersin.org
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. Since the approval
of ipilimumab in 2011, a total of nine ICIs have gained indications for various solid and …
of ipilimumab in 2011, a total of nine ICIs have gained indications for various solid and …
The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report
W Deng, J Chen, XY Deng - Frontiers in Immunology, 2024 - frontiersin.org
Background Extensive-stage small-cell lung cancer (ES-SCLC) is highly malignant, with
early metastasis and high recurrence. Since therapeutic options are limited, ES-SCLC has a …
early metastasis and high recurrence. Since therapeutic options are limited, ES-SCLC has a …
The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events
A Ladouceur, A Ezdoglian, JA Sparks… - Rheumatic …, 2024 - rheumatic.theclinics.com
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment over the past
decade. ICIs harness a patient's own immune system to fight cancer. However, a Division of …
decade. ICIs harness a patient's own immune system to fight cancer. However, a Division of …
Immune checkpoint inhibitor‐induced asthma and chronic obstructive pulmonary disease overlap in patient with adenocarcinoma
Y Hayakawa, T Kawaguchi, K Yamasaki… - Respirology Case …, 2023 - Wiley Online Library
A 67‐year‐old current smoker Japanese man, with no history of asthma, was diagnosed with
lung adenocarcinoma. He received first‐line chemotherapy with carboplatin, pemetrexed …
lung adenocarcinoma. He received first‐line chemotherapy with carboplatin, pemetrexed …